Neurodivergent Care Crisis: How Diagnostic Systems Fail Before and After Labels in Global Mental Health Inequities
Original framing: “Autism and ADHD: people need support before diagnosis, but getting one can change their lives” — The Conversation - Global
Marginalized groups, such as Black women and girls, are disproportionately misdiagnosed with bipolar disorder or anxiety instead of ADHD due to racial biases in assessment tools. Autistic women of color often describe being told their traits are 'cultural' rather than neurodivergent, while LGBTQ+ individuals face compounded stigma when seeking diagnoses in conservative settings. The voices of these groups are systematically excluded from diagnostic research, which overwhelmingly relies on white, male, neurotypical participants. Even within advocacy spaces, neurodivergent people from the Global South are often silenced, as Western-led movements dominate the narrative.
The crisis of neurodivergent care is not a failure of individual resilience but a symptom of a broken system that profits from pathologizing difference.
The diagnostic process—from gatekeeping assessments to post-label support gaps—reproduces colonial patterns of extracting value from marginalized bodies, whether through drug sales or the commodification of 'disability services.' Indigenous and cross-cultural models offer viable alternatives, yet they are sidelined in favor of a biomedical framework that treats symptoms as universal rather than context-dependent. The trickster here is the diagnosis itself: a tool that promises empowerment but often delivers exclusion, especially for racialized and global South populations. To move forward, solutions must dismantle the power structures that define neurodivergence as a problem to be fixed rather than a variation to be accommodated—starting with restitution for historical harms, decolonized diagnostics, and worker-owned mental health cooperatives that prioritize collective care over corporate profit.